T-cell-originated protein kinase (TOPK) is highly expressed in several cancer cells and promotes tumorigenesis and progression, and therefore, it is an important target for drug treatment of tumor. Pantoprazole (PPZ) was identified to be a TOPK inhibitor from FDA-approved drug database by structure based virtual ligand screening. Herein, the data indicated that pantoprazole inhibited TOPK activ...

BACKGROUND Stress ulcer prophylaxis (SUP) using ranitidine, a histamine H2 receptor antagonist, has been associated with an increased risk of ventilator-associated pneumonia. The proton pump inhibitor (PPI) pantoprazole is also commonly used for SUP. PPI use has been linked to an increased risk of community-acquired pneumonia. The objective of this study was to determine whether SUP with pantop...

PURPOSE Limited drug distribution within solid tumors is an important cause of drug resistance. Basic drugs (e.g., doxorubicin) may be sequestered in acidic organelles, thereby limiting drug distribution to distal cells and diverting drugs from their target DNA. Here we investigate the effects of pantoprazole, a proton pump inhibitor, on doxorubicin uptake, and doxorubicin distribution and acti...

Objective: To discuss the role of a proton pump inhibitor (pantoprazole) as a cause of night sweats in an older person. Methods: Our case involves a 73 year-old man who experienced night sweats while taking pantoprazole to treat gastroesophageal reflux disease. Results: Night sweats disappeared ten days after ceasing pantoprazole. They recurred two months later, one week after recommencing pant...

BACKGROUND Short-term intravenous co-administration of famotidine and pantoprazole is used by some veterinarians to treat gastrointestinal bleeding in critically ill dogs. However, clinical studies have not evaluated the efficacy of combination acid suppressant treatment in dogs. HYPOTHESIS/OBJECTIVES To compare the effect of intravenous co-administration of famotidine and pantoprazole to mon...

Since the assay method for pantoprazole in pantoprazole pellets is not described in current pharmacopoeias (USP, BP), the aim of this work was to develop and validate a simple, precise and accurate method for determination of pantoprazole in pantoprazole pellets. Separation was achieved on a reversed-phase C8 column (250 x 4.6 mm i.d.; 5 a mixture of phosphate buffer pH 3.0 and acetonitrile as ...

BACKGROUND Health-related quality of life (HRQoL) is impaired in untreated patients with gastroesophageal reflux disease (GERD). In the absence of an objective marker such as erosions, assessment of treatment efficacy can be based on symptoms and HRQoL. OBJECTIVE To evaluate changes in HRQoL during treatment with pantoprazole or nizatidine in patients with GERD. METHODS This was a prospecti...

BACKGROUND Pantoprazole is a selective inhibitor of the gastric H+/K+-ATPase with a low potential to interact with the cytochrome P450 enzyme system. Since pantoprazole is metabolized in the liver to metabolites which are mainly cleared by the renal route, it was the aim of this study to investigate its pharmacokinetics in patients with end-stage renal failure undergoing regular haemodialysis. ...

BACKGROUND Proton pump is an integral membrane protein that is ubiquitous ATP binding cassette (ABC) involved in many transport processes in all living organisms, among which a specialized form of pump, so called p-type proton pump, exists in the parietal cells of stomach. Though proton pump inhibitors (PPIs) are frequently prescribed to prevent nonsteroidal anti-inflammatory drugs (NSAIDs)-ind...